Trial reportEuropean radiology2012
Management of peripheral arterial interventions with mono or dual antiplatelet therapy--the MIRROR study: a randomised and double-blinded clinical trial.
Trial report in European radiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02798913 (Effects of Prolonged Dual Antiplatelet Therapy With Clopidogrel Plus Acetylsalicylic Acid), which is not on this map. Cited by 62 papers, 11 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Prolonged Dual Antiplatelet Therapy With Clopidogrel Plus Acetylsalicylic Acid (ASA) After Percutaneous Lower Extremity Revascularization in Patients With Peripheral Arterial Disease
Who cites it
62 citing papers in PubMed, 11 syntheses or guidelines pooled it.
- Optimal Antithrombotic Therapy for Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis.Journal of the American Heart Association · 2026Pooled it
- A systematic review and meta-analysis of the impact of clopidogrel responsiveness on ischemic and bleeding complications after noncoronary endovascular procedures.Journal of vascular surgery · 2026Pooled it
- Pooled it
- Pooled it
- Efficacy and Safety of Antiplatelet Therapies in Symptomatic Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis.Current vascular pharmacology · 2021Pooled it
- Efficacy and Safety of Rivaroxaban Compared with Other Therapies Used in Patients with Peripheral Artery Disease Undergoing Peripheral Revascularization: A Systematic Literature Review and Network Meta-Analysis.Cardiovascular therapeutics · 2021Pooled it
- Global vascular guidelines on the management of chronic limb-threatening ischemia.Journal of vascular surgery · 2019Guideline
- Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events.The Cochrane database of systematic reviews · 2017Pooled it
- Guideline
- Guideline
- Pooled it
- A multicenter, randomized, open-labelled, non-inferiority trial of sustained-release sarpogrelate versus clopidogrel after femoropopliteal artery intervention.Scientific reports · 2023Trial
- Trial
- CIRSE Standards of Practice for the Endovascular Management of Acute Lower Limb Ischaemia.Cardiovascular and interventional radiology · 2026Article
- Impact of 1-month dual antiplatelet therapy after treatment with drug-coated balloon for femoropopliteal artery disease.Heart and vessels · 2026Article
- Case Report: A successful percutaneous revascularization of bilateral acute limb ischemia caused by an aortic saddle embolism in a patient with mitral stenosis.Frontiers in cardiovascular medicine · 2026Article
- Oral Anticoagulant Management for Peripheral Vascular Disease.Advances in surgery · 2025Review
- Markers of optimal medical therapy are associated with improved limb outcomes after elective revascularization for intermittent claudication.Journal of vascular surgery · 2025Article
- Medical Therapy for Peripheral Artery Disease.Current cardiology reports · 2024Review
- Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the influence of dual antiplatelet therapy vs. aspirin alone on local platelet activation and clinical endpoints in patients with PAD treated with endovascular therapy.
methodsPatients received either 500 mg aspirin and 300 mg clopidogrel before intervention followed by a daily dose of 100 mg aspirin and 75 mg clopidogrel for 6 months, or the same doses of aspirin plus placebo instead of clopidogrel. Primary endpoints were local concentrations of platelet activation markers β-thromboglobulin and CD40L, and the rate of patient's resistant to clopidogrel. Secondary endpoints included the clinical development 6 months after the intervention.
resultsEighty patients, 40 in each group, were enrolled. The median peri-interventional concentration of β-TG was 224.5 vs. 365.5 (P = 0.03) in the clopidogrel and placebo group. The concentration of CD40L was 127 and 206.5 (P = 0.05). Thirty per cent of patients who had received clopidogrel were resistant. Two clopidogrel and eight placebo patients required TLR (P = 0.04). The clopidogrel patients who needed revascularisation were both resistant to clopidogrel. Minor bleeding complications occurred in one clopidogrel and two placebo patients.
conclusionDual antiplatetet therapy reduces peri-interventional platelet activation and improves functional outcome without higher bleeding complications. An individual tailored dual antiplatelet therapy seems desirable for endovascularly treated patients with PAD.
Indexed as
Identifiers
22569995What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.